Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)

About the company

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. It offers Zygel product which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Sector

Health Technology

Industry

Pharmaceuticals: Other

Employees

28

CEO

Armando Anido

Exchange

NASDAQ

Website

http://www.zynerba.com

$0.00M

Total Revenue

28

Employees

$85.79M

Market Capitalization

-2.39

Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin

Operating Margin (in %)

Total operating margin

Net Margin (in %)

Total net margin

Dividend Yield (in %)

Dividend per share

$0

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
Horizon Therapeutics Plc HZNP 12018.30 1376.00 5.12 18.95 43.06
Catalent, Inc. CTLT 10896.37 2872.00 5.47 104.47 3.63
Perrigo Co. Plc PRGO 7558.29 4837.00 1.30 51.56 3.02
Jazz Pharmaceuticals Plc JAZZ 6076.20 2188.00 2.10 22.21 12.81
Bausch Health Cos., Inc. BHC 6068.07 8597.00 8.47 -3.21 -21.96
United Therapeutics Corp. UTHR 5049.92 1443.00 1.75 9.75 36.59
MyoKardia, Inc. MYOK 4249.02 34.00 12.35 -13.70 -201.73
Axsome Therapeutics, Inc. AXSM 2906.40 None 19.72 -32.31 None
Pacira Biosciences, Inc. PCRX 2427.60 435.00 6.51 -5780.00 -0.02
ArQule, Inc. ARQL 2240.00 5.00 15.75 -55.56 -808.06
SAGE Therapeutics, Inc. SAGE 2231.84 9.00 2.62 -3.45 -413.06
Corcept Therapeutics, Inc. CORT 2013.00 335.00 4.62 18.97 31.64
Prestige Consumer Healthcare, Inc. PBH 1863.54 963.00 1.57 13.14 14.77
Revolution Medicines, Inc. RVMD 1798.91 48.00 4.67 -25.41 -146.29
Madrigal Pharmaceuticals, Inc. MDGL 1558.65 0.00 4.16 -15.26 -624.74
Ironwood Pharmaceuticals, Inc. IRWD 1548.02 440.00 -21.91 18.26 19.14
Innoviva, Inc. INVA 1520.98 285.00 3.60 7.87 66.41
Intercept Pharmaceuticals, Inc. ICPT 1446.72 272.00 -43.06 -4.22 -127.53
Portola Pharmaceuticals, Inc. PTLA 1329.78 121.00 19.53 -4.77 -232.73
Supernus Pharmaceuticals, Inc. SUPN 1309.50 402.00 2.08 11.23 28.90
Theravance Biopharma, Inc. TBPH 1232.34 88.00 -8.65 -4.99 -280.80
Zogenix, Inc. ZGNX 1225.80 5.00 3.35 -2.88 -241.62
Revance Therapeutics, Inc. RVNC 1161.84 0.00 4.59 -6.23 41.82
Amphastar Pharmaceuticals, Inc. AMPH 996.66 327.00 2.49 19.56 15.90
Endo International Plc ENDP 784.32 3014.00 -1.07 -2.80 -9.09
BellRing Brands, Inc. BRBR 745.68 954.00 -0.40 5.66 13.98
Eagle Pharmaceuticals, Inc. EGRX 678.30 192.00 3.65 269.17 1.29
Assembly Biosciences, Inc. ASMB 667.58 16.00 2.99 -6.71 -601.75
Aerie Pharmaceuticals, Inc. AERI 613.18 79.00 4.86 -3.03 -252.92
Collegium Pharmaceutical, Inc. COLL 582.76 299.00 4.17 -45.11 -4.21
Intersect ENT, Inc. XENT 577.76 102.00 5.45 -11.57 -48.61
Catalyst Pharmaceuticals, Inc. CPRX 528.58 119.00 5.15 12.05 36.09
Anika Therapeutics, Inc. ANIK 494.90 125.00 1.71 17.85 22.73
BioDelivery Sciences International, Inc. BDSI 388.24 130.00 5.55 -52.75 -5.01
Albireo Pharma, Inc. ALBO 326.82 11.00 3.32 -4.28 -730.55
ANI Pharmaceuticals, Inc. ANIP 326.76 203.00 1.67 -209.46 -0.67
MEI Pharma, Inc. MEIP 275.56 5.00 4.74 -7.06 -539.48
Mallinckrodt Plc MNK 199.08 3037.00 0.11 -0.17 -39.56
Agile Therapeutics, Inc. AGRX 147.85 None 2.41 -7.16 None
Marinus Pharmaceuticals, Inc. MRNS 146.79 0.00 5.68 -2.18 None
Cerecor, Inc. CERC 118.22 7.00 7.56 -5.24 -429.22
Ampio Pharmaceuticals, Inc. AMPE 98.67 1.00 69.00 -5.31 None
Evoke Pharma, Inc. EVOK 85.92 None 29.83 -12.79 None
Zynerba Pharmaceuticals, Inc. ZYNE 85.79 0.00 1.41 -2.39 -699.94
AcelRx Pharmaceuticals, Inc. ACRX 84.80 2.00 -1.56 -1.51 -644.25
Aclaris Therapeutics, Inc. ACRS 81.18 4.00 1.42 -0.59 None
CTI BioPharma Corp. CTIC 71.98 3.00 3.21 -1.74 -111.83
Adamas Pharmaceuticals, Inc. ADMS 70.84 57.00 -4.52 -0.76 -160.44
Cassava Sciences, Inc. SAVA 63.46 41.00 3.34 -13.92 76.71
Oramed Pharmaceuticals, Inc. ORMP 59.94 3.00 4.83 -4.69 -464.15
SCYNEXIS, Inc. SCYX 48.28 0.00 10.14 -1.25 -30.84
Cumberland Pharmaceuticals, Inc. CPIX 47.70 47.00 0.97 -10.60 -9.59
Natural Alternatives International, Inc. NAII 47.67 114.00 0.65 -12.61 -3.19
IsoRay, Inc. ISR 44.22 9.00 8.25 -13.20 -36.08
Lipocine, Inc. LPCN 40.20 0.00 9.57 -2.68 None
Acasti Pharma, Inc. ACST 35.84 827.00 2.33 -0.58 -7.45
Neos Therapeutics, Inc. NEOS 34.50 65.00 -2.65 -1.97 -26.74
PLx Pharma, Inc. PLXP 25.65 0.00 -2.46 -2.71 119.04
CytRx Corp. CYTR 22.11 0.00 1.60 -3.19 408.46
EyeGate Pharmaceuticals, Inc. EYEG 19.92 3.00 2.48 -1.68 -264.21
Regulus Therapeutics, Inc. RGLS 17.22 0.00 1.52 -0.80 -272.13
Tetraphase Pharmaceuticals, Inc. TTPH 12.15 8.00 0.64 -0.14 -798.18
Intec Pharma Ltd. NTEC 10.18 None 1.31 -0.24 None
Hepion Pharmaceuticals, Inc. HEPA 7.50 None 2.34 -0.63 None
Sonoma Pharmaceuticals, Inc. SNOA 6.44 19.00 1.02 -2.06 -25.58
KemPharm, Inc. KMPH 6.02 15.00 -0.17 -0.35 -120.48
VIVUS, Inc. VVUS 5.83 73.00 -0.13 -0.20 -39.28
Tonix Pharmaceuticals Holding Corp. TNXP 4.62 None 1.16 -0.10 None
Ritter Pharmaceuticals, Inc. RTTR 0.45 None 0.17 -0.03 None

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

Synthetic Cannabinoid Drug Maker Zynerba Plummets 50%

11d ago, source: Benzinga.com on MSN.com

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares retreated to their lowest level since early April following a clinical ...

Zynerba's Zygel Fails in Phase III Fragile X Syndrome Study

10d ago, source: YAHOO!

Zynerba's (ZYNE) shares plunge 48.5% following the study data readout, which demonstrated failure to achieve statistical significance in primary endpoint.

Zynerba's cannabis-based drug for rare genetic disorder fails study

11d ago, source: Nasdaq

Zynerba Pharmaceuticals Inc said on Tuesday its experimental cannabinoid gel, Zygel, did not meet main and key secondary ...

The Week In Cannabis: Stocks Underperform Broader Market, Bad News For Zynerba, Organigram And More

6d ago, source: YAHOO!

It was a relatively quiet week ahead of the Fourth of July. Nonetheless, a handful of announcements had the cannabis markets ...

Zynerba Pharma: Zygel Study Fails To Achieve Statistical Significance In Endpoints

11d ago, source: Business Insider

(RTTNews) - Zynerba Pharmaceuticals, Inc. (ZYNE) reported top line results from the 14-week pivotal CONNECT-FX (clinical study of Cannabidiol in ...

Thinking about buying stock in Zomedica Pharmaceuticals, Nio Inc, Advanced Micro Devices, Norwegian Cruise Line, or Zynerba Pharmaceuticals?

11d ago, source: MarketWatch

Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall ...

Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygelâ„¢ (CBD Gel) in Fragile X Syndrome

12d ago, source: Associated Press

Study Did Not Achieve Statistical Significance in Primary or Key Secondary Endpoints in Full Analysis Set - - Achieved Statistical Significance on Primary Endpoint (p=0.020) in Pre-Planned Ad Hoc ...



Portfolio items

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.